NEWMarkets
Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho
Published on 4/10/2026
AI Summary
Mizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.
Related News
Markets
Stock Futures Flat Ahead of Inflation Data and Iran Ceasefire Updates
Apr 10
Tech
Alphabet (GOOGL) Stock Target Increased Due to Cloud Growth Outlook
Apr 10
Tech
Oracle (ORCL) Stock Rating Reiterated by Mizuho on AI Infrastructure Edge
Apr 10
Markets
Stocks Movements: Lumentum, ServiceNow, and Sandisk Updates
Apr 10